| oxaliplatin / Generic mfg. |
APEC, NCT02965248: Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus no HIPEC in Locally Advanced Colorectal Cancer ( Study) |
|
|
| Recruiting | 3 | 147 | RoW | Standard adjuvant systemic chemotherapy, adjuvant oxaliplatin, 5-FU, and leucovorin calcium (mFOLFOX6), adjuvant oxaliplatin and capecitabine (CapeOx), adjuvant 5-FU and leucovorin calcium (sLV5FU2), adjuvant capecitabine (Cape), Hyperthermic intraperitoneal chemotherapy (HIPEC) with raltitrexed, Intraperitoneal raltitrexed 3 mg/m2, Hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin, I.V. leucovorin calcium 20 mg/m2, I.V. 5-FU 400 mg/m2, Intraperitoneal oxaliplatin 130 mg/m2 | Fudan University | Locally Advanced Colorectal Cancer | 11/21 | 11/23 | | |
NCT03125980: Perioperative Versus Postoperative CapOX Chemotherapy for Locally Advanced Colon Cancer |
|
|
| Recruiting | 3 | 1370 | RoW | capecitabine plus oxaliplatin before and after surgery, capecitabine plus oxaliplatin after surgery | Fudan University | Locally Advanced Colon Cancer | 05/22 | 05/27 | | |
PEPCORLI, NCT02912052: Perioperative Chemotherapy VS Postoperative Chemotherapy for the Treatment of Colon Cancer With Resectable Liver Metastasis |
|
|
| Not yet recruiting | 3 | 240 | RoW | Peri-operative chemotherapy, XELOX, postoperative chemotherapy | The First Affiliated Hospital with Nanjing Medical University | Colon Cancer | 10/23 | 10/23 | | |
| Not yet recruiting | 3 | 140 | Europe | Standard surgical treatment, Proactive management, Standard adjuvant systemic chemotherapy, adjuvant capecitabine and oxaliplatin (CAPOX), adjuvant 5-FU and oxaliplatin (FOLFOX) | University of Roma La Sapienza | Colon Cancer, Intraperitoneal Rectal Cancer | 09/24 | 09/25 | | |
PACHA-01, NCT02494973: Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases |
|
|
| Suspended | 2/3 | 104 | Europe | Oxaliplatin HAI, Oxaliplatin IV, mFOLFOX6, LV5FU2 | Gustave Roussy, Cancer Campus, Grand Paris, National Cancer Institute, France | Colorectal Cancer | 05/28 | 05/28 | | |
| Recruiting | 2 | 100 | Europe | Bevacizumab plus alternating Xelox/Xeliri, Avastin, Xeloda, irinotecan, oxaliplatin | Pia Osterlund | Metastatic Colorectal Cancer | 12/25 | 12/25 | | |
NCT02836977: Maintenance Tegafur-uracil Versus Observation Following Adjuvant Oxaliplatin-based Regimen in Patients With Stage III Colon Cancer After Radical Resection |
|
|
| Active, not recruiting | N/A | 400 | RoW | tegafur-uracil, UFUR | Kaohsiung Medical University Chung-Ho Memorial Hospital | Stage III Colon Cancer | 03/17 | 02/24 | | |
